Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14629809 | 0.81 | SMN1; SMN2 (0.51) | MAOBADORA2AADORA1HTR1AADORA3 | |
| SCHEMBL14887170 | 0.77 | ADORA1 (0.62) | MAOBADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL14887169 | 0.76 | ADORA2A (0.60) | MAOBADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4637336 | 0.76 | ADORA2A (0.60) | MAOBADORA2AADORA1HTR1AADORA3 | |
| Istradefylline SCHEMBL30358491 | 0.75 | ADORA2A (1.00) | MAOBADORA2AADORA1HTR1AADORA3 | |
| Istradefylline SCHEMBL633263 | 0.75 | ADORA2A (1.00) | MAOBADORA2AADORA1HTR1AADORA3 | |
| Istradefylline SCHEMBL29471410 | 0.75 | ADORA2A (1.00) | MAOBADORA2AADORA1HTR1AADORA3 | |
| Istradefylline SCHEMBL5967914 | 0.75 | ADORA2A (1.00) | MAOBADORA2AADORA1HTR1AADORA3 | |
| SCHEMBL3748561 | 0.75 | ADORA2A (0.59) | MAOBADORA2AADORA1HTR1AADORA3 | |
| Istradefylline SCHEMBL633262 | 0.75 | ADORA2A (1.00) | MAOBADORA2AADORA1HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | claimed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | claimed |
| WO-2005079250-A2 | PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| US-11376269-B2 | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML) | INSERM (FR) | 2022-07-05 | — | — | US | disclosed |
| EP-3744348-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INST NAT SANTE RECH MED (FR) | 2022-03-23 | — | — | EP | disclosed |
| EP-3744348-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-12-02 | — | — | EP | disclosed |
| EP-3452092-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INST NAT SANTE RECH MED (FR) | 2020-08-26 | — | — | EP | disclosed |
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | disclosed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | disclosed |
| US-7829332-B2 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2-SCIENCE APS (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-2036567-A2 | Modulation of the P2Y2 receptor pathway | P2-Science APS (DK) | 2009-03-18 | — | — | EP | disclosed |
| US-20070149555-A1 | Prophylatic and/or therapeutic agents for chronic musculoskeletal pain | KYOWA HAKKO KOGYO CO., LTD (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149555-A1 | Prophylatic and/or therapeutic agents for chronic musculoskeletal pain | KYOWA HAKKO KOGYO CO., LTD (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2005079250-A2 | PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2RY2, P2RY1, P2RY11 | MAOB 982/4885ADORA2A 19/4885ADORA1 22/4885 |
| US-20070149555-A1 | Prophylatic and/or therapeutic agents for chronic musculoskeletal pain | ADORA2A, ADORA2B, ADORA3 | MAOB 1735/4885ADORA2A 1/4885ADORA1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.